Nov 8 (Reuters) - IMV Inc IMV.TO :
* IMV INC. ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* IMV INC - QTRLY DILUTED LOSS PER SHARE C$0.16
* IMV INC - TOPLINE INTERIM RESULTS FROM DECIDE1 IN ADVANCED OVARIAN CANCER EXPECTED DURING Q1 2020
* IMV INC - TOPLINE RESULTS FROM PHASE 2 BASKET TRIAL (MULTIPLE TUMORS) OF DPX-SURVIVAC IN 1H 2020.
* IMV INC - AT SEPTEMBER 30, 2019, CORPORATION HAD CASH AND CASH EQUIVALENTS OF $21.4 MILLION
* IMV INC - EXPECTS TOPLINE RESULTS FROM PHASE 2 SPIREL TRIAL (DLBCL) IN 1H 2020